F30-F39
Conditions
Interventions
Group 1: Observation arm: Either prospectively in 3 visits or retrospectively in 1 visit, the Hamilton depression score at the start of treatment and after approx. 12 weeks and the medication list are
Sponsors
Institut für Experimentelle und Klinische Pharmakologie, UKSH, Campus Kiel
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Informed consent • (Planned) use of at least one of the following antidepressants: o citalopram o sertraline o venlafaxine o paroxetine o mirtazapine • (Planned) assessment of Hamilton depression scores (HAM-D17)
Exclusion criteria
Exclusion criteria: • Not of legal age • Non-compliance and other study-endangering factors as determined by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Specificity, precision and limits of quantification of phenotyping 2. Concordance of multiple genotyping | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Concordance of the genetically predicted phenotype to the measured phenotype 2. Correlation of these phenotypes with the change in depth of depression (Hamilton score) and dose 3. Scatter of all target values for future case number planning 4. Frequency of prescribing of certain antidepressants and co-medication 5. Distribution of patients in the 9-field TDM table | — |
Countries
Germany
Contacts
Public ContactRuwen Böhm
Institut für Experimentelle und Klinische Pharmakologie, UKSH, Campus Kiel
Outcome results
None listed